Our Company

Overview

Fractyl is a clinical-stage medical technology company developing innovative procedures and devices to address insulin resistance and restore metabolic health.

We are currently focused on treating two highly prevalent metabolic diseases: type 2 diabetes and nonalcoholic steatohepatitis (NASH). Our mission is to alleviate the daily burdens of disease management for patients, empower physicians with a safe and reliable therapeutic treatment, and lower the tremendous human and financial costs of metabolic disease complications for patients, hospitals, and payers.

 

We have created Revita™ duodenal mucosal resurfacing (DMR), an investigational, minimally invasive, same-day clinical procedure designed to address the intestinal cause of insulin resistance and restore metabolic health in patients suffering from these conditions. The Revita™ DMR procedure and device are currently being evaluated in clinical trials.

Blurb1

Leadership

Management

Harith Rajagopalan, M.D., Ph.D.

Harith Rajagopalan, MD, PhD

Co-Founder and CEO

Jay Caplan

Jay Caplan

Co-Founder and President

Lisa Davidson

Lisa Davidson

Chief Financial Officer

Nimesh Shah

Nimesh Shah

Chief Business Officer

Eric Bannon

Eric Bannon

Vice President of Regulatory Affairs

Jon Fitzgerald

Jon Fitzgerald

Vice President of Quality Assurance

Ella Kirby

Ella Kirby

Vice President of Clinical Affairs

David Maggs

David Maggs

Chief Medical Officer

Len Rosberg

Len Rosberg

Vice President of Manufacturing

Darin Wilson

Darin Wilson

Vice President of International

top

Board

Allan Will

Chairman, Fractyl

Jay Caplan

Co-Founder and President, Fractyl

Brian Dovey

Partner, Domain Associates, LLC

Chris Gabrieli

Partner, Bessemer Venture Partners

Stan Lapidus

President, CEO and Founder, SynapDX

Harith Rajagopalan,
MD, PhD

Co-Founder and CEO, Fractyl

Ajay Royan

Co-Founder and Managing General Partner, Mithril

top

Scientific Advisors

Alan Cherrington, PhD, Chairman

Professor of Molecular Physiology and Biophysics, Professor of Medicine & Jacquelyn A. Turner and Dr. Dorothy J. Turner Chair in Diabetes Research, Vanderbilt University, Nashville, Tennessee; Past-President of American Diabetes Association

Sir George Alberti, MD

Chair of Diabetes UK, Senior Research Fellow at the Imperial College, Emeritus Dean of Medicine at the University of Newcastle upon Tyne, Former President of the Royal College of Physicians, London, United Kingdom; Past-President of International Diabetes Federation

John Amatruda, MD

Former Senior Vice President and Franchise Head for Diabetes and Obesity, Merck & Co., New York City, New York

David Cummings, MD

Professor in the Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, Washington

Lee Kaplan, MD, PhD

Director of the Obesity, Metabolism, and Nutrition Institute & Founding Director of the Weight Center, Massachusetts General Hospital (MGH); Associate Professor of Medicine at Harvard Medical School, Boston, Massachusetts

Carel le Roux, MD, PhD

Professor, Head of Pathology and Chair of Experimental Pathology, University College Dublin, Ireland

Geltrude Mingrone, MD, PhD

Chief of the Division of Obesity and Metabolic Diseases & Professor of Medicine at Catholic University, Rome, Italy

Francesco Rubino, MD

Professor and Chair of Bariatric and Metabolic Surgery, King’s College London, United Kingdom

top

Medical Advisors

Jacques Deviere, MD, PhD

Professor of Medicine and Chairman of the Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Brussels, Belgium

Jacques Bergman, MD, PhD

Professor of Gastrointestinal Endoscopy, University of Amsterdam’s Faculty of Medicine, Amsterdam, The Netherlands

Guido Costamagna, MD

Full Professor of Surgery & Director of the Digestive Endoscopy Unit, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy

Steven Edmundowicz, MD

Professor of Medicine, Chief of Endoscopy & Director of Interventional Endoscopy, Washington University School of Medicine and Barnes Hospital, St. Louis, Missouri

Manoel Galvão Neto, MD

Scientific Director, Gastro Obeso Center, São Paulo, Brazil; Clinical Associate Professor of Surgery, Florida International University, Miami, Florida

Gregory G. Ginsberg, MD

Professor of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Robert Hawes, MD

Medical Director, Florida Hospital Institute for Minimally Invasive Therapy, Orlando, Florida

Horst Neuhaus, MD

Professor of Medicine & Head of the Department of Internal Medicine, Evangelisches Krankenhaus Düsseldorf, Teaching Hospital of the University of Düsseldorf, Düsseldorf, Germany

Lee Swanstrom, MC, FACS

Clinical Professor of Surgery, Oregon Health & Science University; Surgeon, Division of Gatrointestinal and Minimally Invasive Surgery, The Oregon Clinic; Director of Innovation, Institutes des Hôpitaux Universitaires (IHU), Strasbourg, France

Christopher Thompson, MD

Director of Therapeutic Endoscopy, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Ella Kirby

Vice President of Clinical Affairs

Ella Kirby is VP Clinical for Fractyl. She has over twenty years of experience in global clinical development with expertise in both clinical operations and program management. She served as VP of Global Clinical Operations and Program Management at Aegerion Pharmaceuticals, where she was integral to the development and approval of the company’s first marketed drug, Juxtapid® (lomitapide) approved by the U.S. Food and Drug Administration and by the European Medicines Agency for the treatment of a rare genetic lipid disorder, homozygous Familial Hypercholesterolemia (HoFH). Her multi-therapeutic background includes a focus on rare genetic diseases, oncology, and interventional cardiology. She has a broad and varied experience with early stage companies and has played a critical role in a number of other successful regulatory filings, including Angiomax ®, Kalbitor ®, and TNKase®. Ella holds a BS in Biochemistry and pharmacology from the University of Southampton, UK.

CLOSE
Brian Dovey

Partner, Domain Associates, LLC

Brian has been a partner of Domain since 1988, where he has led innovative investments not only in life sciences companies but also in establishing and directing new initiatives, such as the collaboration with Domain and Rusnano.

Since joining Domain, he has served on the board of directors of more than 35 private and public companies and has been chairman of six. He is currently on the board of two public companies: Orexigen Therapeutics and REVA Medical.

Prior to Domain, Brian spent six years at Rorer Group (now part of sanofi-aventis). As president of Rorer from 1986 to 1988, he was the primary architect of this company’s strategic shift to pharmaceuticals that resulted in a doubling of annual sales to approximately $1 billion. Previous to that, Brian was president of Survival Technology, a start-up medical products company whose sales growth placed it in the top ten of the Inc 100. He received his B.A. in mathematics from Colgate University and his MBA from Harvard Business School.

Brian was former chairman and currently serves on the board of directors of both the Center for Venture Education (Kauffman Fellows Program) and the Wistar Institute, a leader in preclinical bio-medical research in the non-profit sector. He is also a member of the Board of Trustees of the La Jolla Playhouse.

Brian served as chairman of the National Venture Capital Association. He is a trustee emeritus of Germantown Academy and is a former trustee of the University of Pennsylvania School of Nursing and the Sanford-Burnham Medical Research Institute. He is also a former board member of the industry associations representing the medical device industry as well as the association representing consumer pharmaceuticals.

CLOSE
Ajay Royan

Mithril Co-Founder and Managing General Partner

Ajay Royan created and runs Mithril, a growth fund that makes concentrated investments in transformative and durable technology companies around the world. Ajay and his team partner with innovators building companies in industries as diverse as cybersecurity, advanced medical devices, and fusion energy. Before forming Mithril, Ajay was a member of the core team that grew Clarium Capital into a multi-billion dollar macro fund. He serves as an external advisor to Oak Ridge National Labs and the University of Michigan Risk Science Center. He was educated at Yale.

CLOSE
Stan Lapidus

President, CEO and Founder of SynapDX

Stan Lapidus is an experienced life-science entrepreneur and inventor with over 30 issued U.S. patents. He founded SynapDX, a new company developing diagnostic tests for the early detection of autism, and currently serves as President and CEO. Prior to SynapDX, Stan founded and led Cytyc, EXACT Sciences and Helicos BioSciences, and holds academic appointments at Tufts and MIT. From 2002 to 2012 Stan served as a trustee of Cooper Union, his alma mater. He was recently inducted into the College of Fellows of the American Institute of Medical and Biological Engineering.

CLOSE
Chris Gabrieli

Partner, Bessemer Venture Partners

Chris Gabrieli, a partner in Bessemer’s Cambridge office, joined the firm in 1986 to launch its healthcare practice. In 25 years of investing with Bessemer, he has invested broadly in healthcare and other industries. He currently focuses on biotechnology, healthcare services and education. Prior to his career at Bessemer, Chris founded and served as CEO of GMIS, a healthcare-software company he co-founded and helped build, take public and sell to the leading industry consolidator, McKesson. Chris graduated from Harvard University with a B.A. in history and science and completed two years of the Columbia College of Physicians & Surgeons M.D. program. He is also a leader in education innovation and is founder and chairman of the National Center on Time & Learning and a lecturer at the Harvard Graduate School of Education.

CLOSE
Nimesh Shah

Chief Business Officer

Nimesh Shah is Chief Business Officer of Fractyl. Nimesh brings with him nearly 20 years of venture capital and Wall Street experience specializing in early-stage or growth oriented medical device companies. Prior to joining Fractyl, Nimesh was a partner of Domain Associates, a leading health care venture capital firm, leading that firm’s efforts in medical devices. Previously, Nimesh served in various roles at venture firm Cutlass Capital and investment bank Alex. Brown (now Deutsche Bank). Nimesh received his B.S. in Biomedical Engineering from the Johns Hopkins University.

CLOSE
Allan Will

Chairman, Fractyl

Allan Will is a seasoned executive with extensive experience founding, funding, operating, and selling medical device companies. He currently also serves as Chairman, President and CEO of EBR Systems and Chairman of the Board for Setpoint Medical. Most recently, Allan was Founder, Chairman and CEO of The Foundry, an incubator dedicated to transforming medical device concepts into companies, where he co-founded 11 companies including among others Ardian Inc. and Evalve Inc. Formerly Allan was a founding Managing Director in Split Rock Partners’ Silicon Valley venture capital office, focusing on the therapeutic medical device field. Earlier in his career, Allan spent more than 20 years in operating roles in medical device companies, the last 17 as CEO of various Bay-area venture backed start-ups. Allan currently holds more than 20 issued patents. He earned his M.S. in Management at MIT and his B.S. in Zoology from the University of Maryland.

CLOSE
Darin Wilson

Vice President of International

Darin Wilson is Fractyl’s VP International. He has over twenty years of medical device experience, most recently with Covidien. As the first international employee for Barrx, now Covidien GI Solutions, Darin ran sales and marketing for the International business and trained endoscopists around the world in the use of the Barrx technology. Prior to Covidien, Darin led the European launch of the Endeavor drug-eluting stent for Medtronic. Before that, he was a senior manager of Boston Scientific’s international cardiovascular and endoscopy businesses in Europe and Asia over a span of 16 years. Darin holds a B.A. in Marketing from Stephen F. Austin State University.

Darin Wilson linkedin

CLOSE
Len Rosberg

Vice President of Manufacturing

Len Rosberg is Vice President of Manufacturing for Fractyl. He brings more than twenty years of experience in supply chain management and manufacturing engineering roles for major medical device firms. With over a decade of senior management expertise, Len most recently served as Vice President of Operations for Candela Corporation, and his industry tenure includes positions at Boston Scientific, Thoratec and Baxter International. His technical expertise encompasses reliability engineering, design for manufacturability, and implementation of scalable manufacturing processes. Len holds a B.S. degree in Electrical Engineering from Wentworth Institute of Technology.

Len Rosberg linkedin

CLOSE
David Maggs

Chief Medical Officer

David is Chief Medical Officer of Fractyl.  David is a board certified endocrinologist and most recently served as Chief Medical Officer of GI Dynamics.  Previously, David spent more than a decade at Amylin Pharmaceuticals where he held positions of increasing responsibility, led numerous innovative collaborations and was directly engaged with the global diabetes and endocrine community.  David served as Amylin’s vice president, medical research and development, where he was integral to the development and commercialization of all three of the company’s marketed drugs – Symlin(R), Bydureon(R) and Byetta(R), the first amylin and GLP-1 receptor agonists respectively approved by the U.S. Food and Drug Administration for the treatment of diabetes. Prior to his Amylin tenure, David served as director, diabetes and metabolism, for Parke-Davis (now Pfizer). Previously, he held faculty appointments at the Yale School of Medicine. David initially trained at Guy’s Hospital, London, and later completed his medical and endocrine training at the University of Nottingham.

 

CLOSE
Jon Fitzgerald

Vice President of Quality Assurance

Jon joined Fractyl in October of 2012 and leads the Quality Assurance team. Jon brings 20 years of medical device start-up experience to Fractyl. Prior to Fractyl, Jon served as Director of Quality Assurance at Neuronetics, a company that successfully developed and commercialized a device-based treatment for depression. In this role, Jon was responsible for creating and implementing a quality system, building a high-performance team, ensuring receipt of timely ISO certifications and scaling processes to anticipate company growth and strategy. Previously, Jon held quality engineering and management positions at Animas, a Johnson & Johnson Company, and Kensey Nash, now DSM Biomedical. Throughout his career, Jon has designed and scaled several quality systems, gaining ISO certification for each, while ensuring the successful launch of ten innovative products into the medical device space.

Jon Fitzgerald linkedin

CLOSE
Eric Bannon

Vice President of Regulatory Affairs

Eric Bannon heads Regulatory Affairs for Fractyl. With 30 years of experience in the medical device industry, Eric is a leader in the field. He has held numerous senior management positions in regulatory, clinical, and quality assurance for a variety of large cap and startup medical technology companies. Prior to joining Fractyl in 2011, Eric held the position of VP of Regulatory and Clinical Affairs for Facet Solutions, NDO Surgical, Cortek, and Innovasive Devices. Eric holds a B.S. in Microbiology from the University of Maine.

Eric Bannon linkedin

CLOSE
Lisa Davidson

Chief Financial Officer

Lisa Davidson is Chief Financial Officer for Fractyl. Lisa has more than 25 years of broad corporate finance experience encompassing treasury management, strategic planning, operations finance, and controllership. She served as Vice President of Finance & Administration of Flexion Therapeutics, Inc. Prior to Flexion, Lisa served as Director of Finance at OmniSonics Medical Technologies, Inc. She previously served in various finance, strategy and administration positions at Fisher Scientific International, Inc., Pepsi Bottling Group, and PerkinElmer Inc. Ms. Davidson has been involved in a number of M&A transactions, venture debt and equity financing, and numerous product launches. She holds a BA and an MBA, both from the University of New Hampshire.

Lisa Davidson linkedin

CLOSE
Jay Caplan

Co-Founder and President

Jay Caplan is Co-founder and President of Fractyl and has held leadership positions in the medical device field for twenty years. Prior to founding Fractyl, Jay was the Chief Operating Officer of the Candela Corporation, a world leader in aesthetic devices. Previously, he was Chief Technology Officer and Vice President of Research and Development of InfraReDx, Inc. a venture-backed startup developing a novel cardiovascular imaging system to identify lipid-rich coronary plaques. Prior to InfraReDx, Jay was VP Operations for Thermo Cardiosystems, where he led the team developing the HeartMate II left ventricular assist device. Jay holds a B.S. in Electrical Engineering from M.I.T. and an M.B.A. from The Wharton School.

www.jaycaplan.com
Jay Caplan twitter      Jay Caplan linkedin

CLOSE
Harith Rajagopalan, MD, PhD

Harith Rajagopalan, MD, PhD

Co-Founder and CEO

Dr. Harith Rajagopalan is Co-founder and CEO of Fractyl, having started the company while serving as an Entrepreneur-in-Residence at General Catalyst Partners. Prior to founding Fractyl, Harith was an academic cardiologist and physician-scientist. He received his B.S. in Chemistry from Stanford University and went on to obtain M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, Harith did groundbreaking and award-winning research on intestinal cancers that was published in top medical journals, including Nature and Science. After medical school, Harith trained in internal medicine and clinical cardiology at Brigham and Women’s Hospital and completed a research fellowship at Harvard Medical School.

hrajagopalan twitterhrajagopalan linkedin

CLOSE